Company / Accounts Receivable
PLUS THERAPEUTICS, INC. Accounts Receivable History
FY2011-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$145.0K
FY2018
5-year range
$145.0K / $1.2M
FY2014-FY2018
Trend
+0.0%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 8 years, ranging from $145,000 in FY2018 to $4M in FY2013.
Based on SEC 10-K filings.
$145,000 in FY2018 with a 5-year CAGR of -48.9%.
Declined from $1M to $145,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -48.3%
- 5-Year CAGR
- -48.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -48.9%, indicating a declining trend.
- In FY2018, accounts receivable increased 0.0% year-over-year.
- Peak accounts receivable was recorded in FY2013.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2018 | $145.0K | +0.0% |
| FY2017 | $145.0K | -88.3% |
| FY2016 | $1.2M | +18.1% |
| FY2015 | $1.1M | -15.4% |
| FY2014 | $1.2M | -70.1% |
| FY2013 | $4.2M | +5.8% |
| FY2012 | $3.9M | +89.4% |
| FY2011 | $2.1M | - |
As of FY2018 · SEC 10-K · Updated Jun 28, 2026